Medtronic plc engages in the research, design, manufacture, and sale of products to alleviate pain, restore health, and extend life. The company serves hospitals, physicians, clinicians, and patients in approximately 160 countries worldwide. Segments The company operates in the following segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group, and Diabetes Group. Cardiac and Vascular Group Cardiac Rhythm and Heart Failure Disease Management (CRHF) The CRHF division develops, manufactures, and markets products for the diagnosis, treatment, and management of heart rhythm disorders and heart failure. The company’s products include implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, information systems for the management of patients with CRHF devices, and an integrated health solutions business. The following are the principal products and services offered by the CRHF division: Implantable Cardiac Pacemakers (Pacemakers): The company’s latest generations of pacemaker systems are the Advisa MRI SureScan models, the Micra Transcatheter Pacing System, and the Ensura MRI SureScan model. The Micra Transcatheter Pacing System, which does not have a subcutaneous device pocket, such as conventional pacemaker, and the Advisa MRI SureScan models have received United States (U.S.) Food and Drug Administration (U.S. FDA) approval and Conformite Europeene (CE) Mark approval, while the Ensura MRI SureScan models have received CE Mark approval. Implantable Cardioverter Defibrillators (ICDs): The company’s latest generation ICD is the Evera MRI SureScan, the first ICD system with CE Mark, PMDA (Japan), and U.S. FDA, approval for full-body MRI scans for both 1.5T and 3T scanners. Implantable Cardiac Resynchronization Therapy Devices (CRT-Ds and CRT-Ps): The company’s CRT-Ds is the Amplia/Compia/Claria family of MRI Quad CRT-D SureScan systems. The U.S. FDA and CE Mark approved Amplia and Compia MRI Quad CRT-D SureScan systems are approved for MRI scans on any part of the body. Viva CRT-P is the company’s latest generation device, with respect to CRT-P. AF Products: The company’s portfolio of AF products includes the Arctic Front Advance Cardiac Cryoballoon System designed for pulmonary vein isolation in the treatment of patients with drug refractory paroxysmal AF. Additionally, the company has a second-generation CE Mark approved Phased RF System, PVAC Gold, which uses duty cycled, phased radio frequency energy for the treatment of symptomatic paroxysmal persistent and long-standing persistent AF. Diagnostics and Monitoring Devices: The company’s Reveal LINQ is its newest Insertable Cardiac Monitor (ICM) System. The system is used to record the heart’s electrical activity before, during, and after transient symptoms such as syncope and palpitations to assist in diagnosis. TYRX Products: The company’s TYRX products include the Absorbable Antibacterial Envelope and the TYRX Neuro Absorbable Antibacterial Envelope, which are designed to stabilize electronic implantable devices and help prevent infection associated with implantable pacemakers, defibrillators, and spinal cord neurostimulators. Services and Solutions: The company’s Care Management Services products and services include remote monitoring and patient-centered software to enable care coordination and telehealth nurse support. Its Cath Lab Managed Services business is focused on developing novel partnerships with hospitals to provide services directly related to hospital operational efficiency. Coronary and Structural Heart Disease Management (CSH) The CSH division includes therapies to treat coronary artery disease (CAD), and heart valve disorders. The company’s products include coronary stents and related delivery systems, including a line of balloon angioplasty catheters, guide catheters, guide wires, diagnostic catheters, and accessories, as well as products for the repair and replacement of heart valves, perfusion systems, positioning and stabilization systems for beating heart revascul
medtronic plc (MDT:New York)
20 On Hatch
Lower Hatch Street
Phone: 353 1 438 1700
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for MDT.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact MEDTRONIC PLC, please visit www.medtronic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.